This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Dr. Reddy's Laboratories
Drug Names(s): NN 2344, DRF2593
Description: Balaglitazone is an oral, selective, second generation of PPAR gamma agonist with only partial agonistic properties (partial PPARg agonist).
Deal Structure: In 1997, Dr. Reddy's licensed balaglitazone to Novo Nordisk and in 2004, Novo Nordisk returned this molecule to Dr. Reddy's.
In September 2005, Dr. Reddy's announced it entered into a co-development andcommercialization agreement with Rheoscience A/S, a subsidiary of Nordic Bioscience A/S, for the joint development and commercialization of balaglitazone. Under the terms of the agreement, Rheoscience shall fund all thecosts associated with the Phase III clinical trials of balaglitazone and Dr. Reddy's shall pay Rheoscience a pre-determined amount towards its share of the development costs. Rheoscience will retain the marketing rights to European Union and China and Dr. Reddy's will retain themarketing rights in the territories of United States and rest of the world. Rheoscience shall obtain all necessary regulatory approvals onbehalf of Dr. Reddy's in the United States. On receiving final FDA approval, Dr. Reddy's is to make a pre-determined milestone payment to Rheoscience. The...See full deal structure in Biomedtracker
Partners: Nordic Bioscience
Additional information available to subscribers only: